The 2002 PhRMA Code and Pharmaceutical Marketing: did anybody bother to ask the reps?
After marketing tactics resulted in $1.2 billion fines, the 2002 PhRMA Code attempted to standardize marketing and sales practices. Self-regulation had varied success by other industries and by pharmaceutical industries in other countries. Similarly, the Code addressed negative responses about pharmaceutical's practices but had no provisions for monitoring violations. Representative's (reps) perspectives were assessed using an 18-item instrument with 72 reps from 25 companies. Analyses indicated that reps from bigger companies, PhRMA and non-PhRMA, adhered better. The way reps adhered was split between adhering reluctantly and following faithfully. Two thirds felt it was more difficult to do their jobs, resulting from prior entertainment-based relationships with physicians.
The Erivan K Haub School of Business, Saint Joseph's University, Philadelphia, Pennsylvania 19131-1395, USA. sillup@sju.edu
George P
GP
Sillup
Bill
B
Trombetta
Ronald
R
Klimberg
D004345:Drug Industry / Q000941:ethics / Q000458:organization & administration*; D006801:Humans; D008389:Marketing of Health Services / Q000941:ethics / Q000592:standards*; D012952:Societies / Q000592:standards*